NYSE:DGXHealthcare
A Look At Quest Diagnostics (DGX) Valuation After Barclays Upgrade And Earnings Growth Optimism
Barclays upgraded Quest Diagnostics (DGX) after expressing greater confidence in the company’s organic growth prospects, potential earnings outperformance, and the durability of its core diagnostics business, drawing fresh attention to the stock’s current valuation.
See our latest analysis for Quest Diagnostics.
At a share price of $187.03, Quest Diagnostics has seen a 7.6% year to date share price return and a 17.3% total shareholder return over one year, with the recent analyst upgrade...